Accuryn Medical Partners with Vizient for Advanced Fluid Monitoring

HAYWARD, Calif., Nov. 11, 2026 /CourierPR/ -- Accuryn Medical, a company focused on advancing kidney health monitoring in critical care, has entered into a multi-year agreement with Vizient, a leading healthcare services company, to expand access to its advanced fluid monitoring technology. Through this partnership, eligible Vizient clients will have access to the Accuryn Monitoring System, which provides continuous visibility into urine output, supporting earlier recognition and informed clinical decisions.

The Accuryn Monitoring System automates urine output measurement and offers real-time trends and alerts based on the guidelines established by Kidney Disease: Improving Global Outcomes (KDIGO). This technology is crucial for monitoring acute kidney injury (AKI) in critically ill patients, as changes in urine output can provide early indications of kidney distress. The system combines smart urinary catheter technology with urine output monitoring, core body temperature measurement, and continuous intra-abdominal pressure monitoring, offering comprehensive insights into patient health.

The agreement aims to provide a purchasing pathway for eligible Vizient clients seeking to implement advanced kidney health and fluid monitoring. Hospitals interested in product availability, contract pricing activation, or a demonstration can contact Accuryn Medical directly.

This partnership is significant as it enhances the availability of Accuryn Medical's technology to a broader range of healthcare institutions, potentially improving patient outcomes and clinical decision-making processes. The Accuryn Monitoring System's ability to provide continuous urine output data can be particularly beneficial in intensive care units where early detection of AKI is critical for patient care.

By expanding access to this technology, Accuryn Medical and Vizient are working together to address the challenges faced by healthcare providers in monitoring and managing acute kidney injury. The collaboration underscores the companies' commitment to advancing patient care and improving health outcomes in critical care settings.